STOCK TITAN
  1. Home
  2. News
  3. DMK

DMK Pharmaceuticals Corporation - $DMK STOCK NEWS

Welcome to our dedicated page for DMK Pharmaceuticals Corporation news (Ticker: $DMK), a resource for investors and traders seeking the latest updates and insights on DMK Pharmaceuticals Corporation stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect DMK Pharmaceuticals Corporation's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of DMK Pharmaceuticals Corporation's position in the market.

News
DMK Pharmaceuticals Commences Restructuring Proceeding
Rhea-AI Summary
DMK Pharmaceuticals Corporation has filed for Chapter 11 bankruptcy, seeking to restructure its business and manage its properties as 'debtors-in-possession' under the U.S. Bankruptcy Code. The company aims to continue its operations while addressing obligations related to employee wages, salaries, and benefits. The Court is expected to approve the relief sought in these motions on an interim basis.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News
DMK Pharmaceuticals Regains Full Rights to Commercialize ZIMHI
Rhea-AI Summary
DMK Pharmaceuticals Corporation (Nasdaq: DMK) announces plans to seek commercialization partnerships in the United States, Canada, and Europe to expand revenue generation for ZIMHI® (naloxone) after regaining full rights from US WorldMeds, LLC. The company aims to target first responders in the United States, where market data shows significant demand for the product. CEO Eboo Versi, M.D., Ph.D., expresses excitement about engaging with partners to drive long-term growth and maximize benefits to patients and stakeholders.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
28.81%
Tags
none
-
News
DMK Pharmaceuticals Regains Full Rights from US WorldMeds for SYMJEPI® and Provides Corporate Update
Rhea-AI Summary
DMK Pharmaceuticals Corporation (DMK) (NASDAQ: DMK) announced its reacquisition of the rights to its SYMJEPI® (epinephrine) Injection products from USWM, LLC, and its plans to seek out license opportunities for SYMJEPI® in the US and globally to maximize value for shareholders.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.16%
Tags
none
News
DMK Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update
Rhea-AI Summary
DMK Pharmaceuticals Corporation (NASDAQ: DMK) rebranded and appointed a new leadership team to reduce opioid-related deaths, increase shareholder value, and presented preclinical data for DPI-125 at the Society of Neuroscience Annual Meeting 2023. The company is focused on developing and commercializing products to combat the fentanyl and substance use disorder crises.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.89%
Tags
earnings
-
News
DMK Pharmaceuticals Announces Presentation of Preclinical Results Comparing Effects of DPI-125 on Opioid Withdrawal Behaviors Versus Standard of Care for Opioid Use Disorder at SfN Neuroscience 2023
Rhea-AI Summary
DMK Pharmaceuticals Corporation (NASDAQ: DMK) Announces Preclinical Results Comparing DPI-125 to Methadone and Buprenorphine for Opioid Use Disorder Treatment
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.16%
Tags
clinical trial
-
News
DMK Pharmaceuticals Announces Inducement Option Grant Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
DMK Pharmaceuticals Corporation (NASDAQ: DMK) has granted a stock option to John W. Dorbin, Jr., the newly hired General Counsel and Corporate Secretary. The option allows him to purchase 70,000 shares of common stock at an exercise price of $0.58 per share. The option has a ten-year term and vests over a four-year period.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.7%
Tags
none
News
DMK Pharmaceuticals Announces Inducement Option Grant Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
DMK Pharmaceuticals grants stock option to new CFO
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News
DMK Pharmaceuticals Restructures Executive Team to Support Next Phase of Growth
Rhea-AI Summary
DMK Pharmaceuticals announces management changes to optimize leadership structure
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.69%
Tags
none
Stock DMK logo
DMK Pharmaceuticals Corporation

Nasdaq:DMK

DMK Rankings

N/A Ranked by Market Cap
N/A Ranked by Stock Gains
N/A Ranked by Dividends

DMK Stock Data

2.34M
10.05M
9.26%
2.44%
2.1%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
San Diego

About DMK

adamis pharmaceuticals corporation (nasdaq: admp) is a specialty biopharmaceuticals company focused on developing and commercializing products in the therapeutic areas of respiratory disease, allergies, oncology and immunology. its specialty pharmaceutical division currently has four products in its pipeline including the epinephrine injection pre-filled syringe (pfs) for use in the emergency treatment of anaphylaxis, apc-1000 and apc-5000 (dry powder inhaler) for the treatment of asthma and chronic obstructive pulmonary disease (copd), and apc-3000, a hydrofluoroalkane (hfa) inhaled nasal steroid product for the treatment of allergic rhinitis. this division’s focus is to create low cost therapeutic alternatives to existing treatments in large markets. adamis will pursue 505(b)(2) regulatory approval filings in order to minimize costs and shorten the time to market in this division. within its biotechnology division, the company has four products under development include telob-vax, a